Analysts See $-0.12 EPS for Sophiris Bio, Inc. (SPHS)

May 16, 2018 - By Betty Noble

Sophiris Bio, Inc. (NASDAQ:SPHS) LogoInvestors sentiment increased to 2.8 in Q4 2017. Its up 2.16, from 0.64 in 2017Q3. It is positive, as 2 investors sold Sophiris Bio, Inc. shares while 3 reduced holdings. 8 funds opened positions while 6 raised stakes. 1.87 million shares or 14.89% more from 1.63 million shares in 2017Q3 were reported.
Virtu Ltd has 169,790 shares. 137,331 were accumulated by Goldman Sachs Grp Inc Inc. The California-based Palo Alto Ltd Liability has invested 0.02% in Sophiris Bio, Inc. (NASDAQ:SPHS). Comml Bank Of America De reported 3,338 shares stake. Susquehanna Int Gru Ltd Liability Partnership owns 13,783 shares or 0% of their US portfolio. 55,907 were reported by Sabby Lc. Geode has 19,042 shares. The Wisconsin-based Northwestern Mutual Wealth Co has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Vanguard Inc holds 0% or 784,834 shares. Wells Fargo Mn stated it has 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Millennium Mgmt Limited Co reported 199,705 shares. Macquarie Limited holds 0% or 3,700 shares in its portfolio. New York-based Edge Wealth Management Ltd has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS). Citadel Lc reported 21,608 shares stake. The New York-based Morgan Stanley has invested 0% in Sophiris Bio, Inc. (NASDAQ:SPHS).

Analysts expect Sophiris Bio, Inc. (NASDAQ:SPHS) to report $-0.12 EPS on May, 21.They anticipate $0.03 EPS change or 33.33 % from last quarter’s $-0.09 EPS. After having $-0.11 EPS previously, Sophiris Bio, Inc.’s analysts see 9.09 % EPS growth. The stock decreased 0.28% or $0.01 during the last trading session, reaching $3.51. About 460,350 shares traded or 89.36% up from the average. Sophiris Bio, Inc. (NASDAQ:SPHS) has declined 26.06% since May 16, 2017 and is downtrending. It has underperformed by 37.61% the S&P500.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company has market cap of $98.07 million. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia , as well as for the treatment of localized low to intermediate risk prostate cancer. It currently has negative earnings. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

Another recent and important Sophiris Bio, Inc. (NASDAQ:SPHS) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018.

Sophiris Bio, Inc. (NASDAQ:SPHS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: